Evicenter
MarkdownMedical informationP&T meetings
Ersodetug (RZ358)

Tumor hyperinsulinism

Manufacturer
Rezolute
Launch
Not announced
Last updated
140 sources

Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care

Limitations of current therapies

4 evidence topics · 36 sources

Summary: surgery and ablation for benign and localized insulinoma
  • Surgical resection is the guideline treatment for localized insulinoma. The NANETS surgical guideline gives a 98% biochemical cure rate and a 6% chance of recurrence at 10 years after resection of a localized insulinoma.
  • Operative morbidity is the main limitation. In 198 patients (106 enucleations and 92 pancreatic resections), the rate of clinically significant pancreatic fistula was 18%, enucleations had a higher reoperation rate than pancreatic resections (8.5% vs 1%), and new exocrine (1.5%) and endocrine (4%) insufficiency followed pancreatic resections only. In 80 patients operated for sporadic insulinoma over three decades, mortality was 6% (n = 5), morbidity 72%, and pancreatic fistula 44%, although surgery was curative in all patients. In 74 patients, an open approach (28 patients) was associated with more grade III/IV complications (32.1% vs 19.6%) and more 30-day readmissions (42.9% vs 17.4%) than a minimally invasive approach (46 patients).
  • Recurrence after resection was 21% at 10 and 20 years in patients with MEN I, and 5% at 10 years and 7% at 20 years in patients without MEN I, in one cohort.
  • EUS-guided radiofrequency ablation is an option in ENETS guidance for localized insulinomas of 2 cm or less in patients unfit for surgery, with confinement to expert centers until long-term survival and recurrence data are available. In a propensity-matched comparison of 89 patients per group, adverse events occurred in 18.0% after ablation and 61.8% after surgery, clinical efficacy was 95.5% and 100%, median follow-up was 23 and 37 months, and 15 lesions (16.9%) recurred after ablation. A randomized trial comparing ablation with surgery (NCT05735912) is registered.
Summary: medical therapy for hypoglycemia in insulinoma
  • Dietary measures (fractioned meals with slowly absorbed carbohydrates, bedtime meals) are the basis of hypoglycemia control; nocturnal tube feeding or IV glucose through a central catheter may be needed in severe recurrent hypoglycemia. The glucagon (Gvoke) label lists insulinoma as a contraindication because glucagon may stimulate insulin release from the tumor, and states that the product is not approved for continuous infusion.
  • Diazoxide is the first-line medical therapy for advanced insulinoma in ENETS guidance and controls hypoglycemia in 50 to 60% of cases according to the NANETS surgical guideline. Dose-limiting adverse effects (fluid retention and edema, palpitations, nausea, anorexia, hirsutism) occur in up to 80% of patients in one review. The label directs discontinuation if diazoxide is not effective after 2 or 3 weeks and warns of fluid retention that may precipitate congestive heart failure, ketoacidosis, nonketotic hyperosmolar coma, and thrombocytopenia. In 20 patients with insulinoma, diazoxide was effective in 9 and ineffective in 9, all 9 responders had benign insulinoma, and 5 patients had unacceptable thrombocytopenia. In 6 patients with inoperable insulinoma, 5 developed edema and 2 congestive heart failure. In a UK survey of 40 patients, side effects occurred in 47%, 59% were symptom free, and 38% had occasional symptoms.
  • Somatostatin analogs can paradoxically aggravate hypoglycemia by suppressing glucagon, so a monitored trial of short-acting octreotide is advised before a long-acting formulation. Octreotide was effective in 10 of 17 patients in one series and 14 of 21 in another. The octreotide LAR and lanreotide labels warn of hypoglycemia or hyperglycemia, and their quoted indications are acromegaly, carcinoid and VIPoma symptoms, and progression-free survival in GEP-NETs. Pasireotide is used off-label; in 17 published cases, 6 (35%) showed no improvement, with no improvement in 55% of aggressive and 16% of indolent insulinomas.
  • Glucocorticoids for refractory hypoglycemia rest on incidental descriptions in ENETS guidance (level of evidence 5, grade D), and chronic use carries weight gain, neuropsychiatric disturbances, hypertension, and opportunistic infections.
Summary: malignant and metastatic insulinoma
  • In 121 patients with malignant insulinoma, resection was performed in 64%, and 5-year overall survival was 84% with surgery and 14% without. A clinical review states that most aggressive malignant metastatic insulinomas “cannot be cured by surgery or ablation procedures alone” and require medical and antitumor treatment.
  • Hypoglycemia control in one malignant insulinoma cohort was 93% with PRRT, 68% with capecitabine-temozolomide, 62% with everolimus, 37.5% with somatostatin analogs, 33.3% with chemotherapy, and 28.6% with streptozocin.
  • Everolimus: ENETS guidance describes limited tolerance. In 12 patients with metastatic insulinoma and refractory hypoglycemia, median time to first recurrence of symptomatic hypoglycemia was 6.5 months, and 3 patients discontinued for cardiac or pulmonary adverse events, which led to two deaths. The manufacturer of ersodetug states that mTOR inhibitors are used off-label.
  • PRRT requires demonstrated somatostatin receptor expression and carries a 2% rate of serious bone marrow disease. In 15 patients treated with lutetium Lu 177 dotatate, hypoglycemia resolved in 14 and recurred in 7 of 14 after a median of 17.7 months; G3/4 myelosuppression occurred in 4 of 15 and hypoglycemia flare requiring hospitalization over 48 hours in 7 of 15. In 26 patients, 5 (19%) had transient hypoglycemia after injection, and hormonal crisis occurred in 3 of 34 patients (9%) with functioning pancreatic tumors in another series.
  • Cytotoxic chemotherapy causes considerable toxicities, and evidence for an independent effect of chemotherapy regimens on hypoglycemia is lacking according to one review.
  • Liver-directed therapy carries a high morbidity risk with high hepatic metastatic load in ENETS guidance. After bland hepatic artery embolization in 20 patients, hypoglycemia recurred in 60% at a median of 2 months; after chemoembolization and radioembolization in 7 patients, mean time to recurrence of intractable hypoglycemia was 21 months.
  • The manufacturer states that tumor-directed therapies do not directly treat hypoglycemia caused by insulinomas or non-islet cell tumors, and that such therapies are deferred because of hypoglycemia.
Summary: non-islet cell tumor hypoglycemia
  • Complete surgical resection is curative for hypoglycemia, but in many cases total resection is delayed or not feasible. In a systematic review of published cases of IGF-2-mediated hypoglycemia, surgery was used in 110 cases (47.2%), and the overall recovery rate was 77% (172 of 223 cases with outcomes).
  • When prompt resection is not feasible, IV glucose or dextrose often does not suffice. Continuous glucagon infusion and parenteral nutrition are limited by the need for continuous IV infusion, and long-term parenteral nutrition is “not a desirable long-term strategy” because of venous access complications, bloodstream infections, liver toxicity, electrolyte imbalances, and cost. In a series of 4 patients with NICTH and liver metastases, glucose did not rise after glucagon in 2.
  • Diazoxide and octreotide have no role in NICTH in one clinical review, which found diazoxide unsuccessful in every case reviewed. In the systematic review, octreotide was used in 9 recovered patients (5.2%) and 9 who died (17.6%) (p = .01). The manufacturer states that diazoxide and somatostatin analogs are not effective for hypoglycemia from IGF-2 tumors.
  • Glucocorticoids, used in 91 cases (39.1%) in the systematic review, are effective only above a patient-specific dose threshold. Minimum effective doses in one review of solitary fibrous tumors were 25 mg/day of prednisolone, 32 mg/day of methylprednisolone, and 2 mg/day of dexamethasone, and recurrence below these thresholds limits long-term use. Recombinant growth hormone at 3 to 12 mg daily has been successful in many cases, cost may limit long-term use, and growth hormone may increase serum big IGF-II. No randomized controlled trials guide therapy.